These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 19055211)

  • 1. Idiopathic anaphylaxis successfully treated with omalizumab.
    Jones JD; Marney SR; Fahrenholz JM
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):550-1. PubMed ID: 19055211
    [No Abstract]   [Full Text] [Related]  

  • 2. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
    Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
    J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
    [No Abstract]   [Full Text] [Related]  

  • 3. Omalizumab monotherapy for bee sting and unprovoked "anaphylaxis" in a patient with systemic mastocytosis and undetectable specific IgE.
    Kontou-Fili K; Filis CI; Voulgari C; Panayiotidis PG
    Ann Allergy Asthma Immunol; 2010 Jun; 104(6):537-9. PubMed ID: 20568389
    [No Abstract]   [Full Text] [Related]  

  • 4. Omalizumab in idiopathic anaphylaxis.
    Warrier P; Casale TB
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):257-8. PubMed ID: 19354075
    [No Abstract]   [Full Text] [Related]  

  • 5. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab.
    Schulze J; Rose M; Zielen S
    Allergy; 2007 Aug; 62(8):963-4. PubMed ID: 17484729
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab.
    Sands MF; Blume JW; Schwartz SA
    J Allergy Clin Immunol; 2007 Oct; 120(4):979-81. PubMed ID: 17931567
    [No Abstract]   [Full Text] [Related]  

  • 7. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
    Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
    Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
    [No Abstract]   [Full Text] [Related]  

  • 8. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract]   [Full Text] [Related]  

  • 9. Ice cream urticaria.
    Ota M; Kawasaki H; Horimoto M
    Am J Med; 2010 Dec; 123(12):e1-2. PubMed ID: 20961525
    [No Abstract]   [Full Text] [Related]  

  • 10. Omalizumab as a therapeutic alternative for chronic urticaria.
    Callejas-Rubio JL; Sánchez-Cano D; Lara MA; Ortego-Centeno N
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):556. PubMed ID: 19055216
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of idiopathic anaphylaxis with omalizumab.
    Sanchez-Valenzuela MC; Garcia-Saucedo JC; Motoa G; Carrillo-Martin I; Gonzalez-Estrada A
    Ann Allergy Asthma Immunol; 2019 Dec; 123(6):612-613. PubMed ID: 31568858
    [No Abstract]   [Full Text] [Related]  

  • 13. Anaphylaxis to vapors of roasting chicken controlled by omalizumab.
    Barnig C; Hilger C; Muti D; Blaumeiser M; Purohit A; Hentges F; de Blay F
    J Investig Allergol Clin Immunol; 2012; 22(6):439-40. PubMed ID: 23101190
    [No Abstract]   [Full Text] [Related]  

  • 14. The appropriate omalizumab patient.
    Karpel J; Bukstein DA; LoNigro R
    Manag Care; 2007 May; 16(5):44-50, 56. PubMed ID: 17552338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of omalizumab in Aspergillus-associated airway disease.
    Pérez-de-Llano LA; Vennera MC; Parra A; Guallar J; Marin M; Asensio O; Ausin P; Borderías L; Fernández C; Granel C; Pérez-Pimiento A; Rubio M
    Thorax; 2011 Jun; 66(6):539-40. PubMed ID: 21398373
    [No Abstract]   [Full Text] [Related]  

  • 17. Successful treatment of idiopathic anaphylaxis in an adolescent.
    Pitt TJ; Cisneros N; Kalicinsky C; Becker AB
    J Allergy Clin Immunol; 2010 Aug; 126(2):415-6; author reply 416. PubMed ID: 20624653
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma.
    Limb SL; Starke PR; Lee CE; Chowdhury BA
    J Allergy Clin Immunol; 2007 Dec; 120(6):1378-81. PubMed ID: 17936893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylaxis due to progesterone hypersensitivity successfully treated with omalizumab.
    Heffler E; Fichera S; Nicolosi G; Crimi N
    J Allergy Clin Immunol Pract; 2017; 5(3):852-854. PubMed ID: 28258855
    [No Abstract]   [Full Text] [Related]  

  • 20. Rituximab and omalizumab in severe, refractory insulin allergy.
    Yong PF; Malik R; Arif S; Peakman M; Amiel S; Ibrahim MA; Gough A
    N Engl J Med; 2009 Mar; 360(10):1045-7. PubMed ID: 19264698
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.